Partnerships

 

ANTABIO’s technology targets major pathogens such as Escherichia coli and Klebsiella pneumoniae, including the multi-resistant NDM-1 strains. To consolidate our product portfolio, we are interested in partnerships in the following topics:

  • Novel approaches targeting other major gram-negative nosocomial pathogens such as Pseudomonas aeruginosa or Acinetobacter baumannii.

  • Control and prevention strategies against gram-negative pathogens that are potential biological warfare agents

ANTABIO’s development model is especially well-suited to bring commercial value to academic research through partnering:

Partner
 Added value from partnering with ANTABIO
High-Throughput Screening Platforms
  • Identification and selection of novel anti Gram-negative compounds
Clinical or Basic Microbiology Research Groups
  • Identification and characterization of antibacterial targets with novel mode of action
  • Development of novel antibacterial screening tools
OTT departments of academic research institutions
  • Licensing opportunities
  • Collaborations through Technology Transfer